Back to results
US 7,507,811 B2Granted
siRNA targeting KRAS
AssigneeDharmacon, Inc.
InventorsAnastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Stephen Scaringe, Steven Read
Life of this patent
Estimating the term…
Abstract
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.
Claims13
An siRNA molecule, consisting of:
- (a) a sense region and an antisense region, wherein said sense region and said antisense region together form a duplex region consisting of 19-30 base pairs and said antisense region comprises a sequence that is the complement of SEQ. ID. NO. 461;
- and (b) from zero to four overhang regions, wherein each overhang region is six or fewer nucleotides in length.
A chemically synthesized double stranded siRNA molecule that directs cleavage of an mRNA via RNA interference, wherein:
- a. each strand of said double stranded siRNA molecule is between 19 and 30 nucleotides in length;
- and
- b. one strand of said double stranded siRNA molecule comprises a sequence that is the complement of SEQ. ID. NO. 461.
An siRNA molecule, wherein said siRNA molecule consists of:
- (a) a sense region, wherein said sense region consists of a sequence that is SEQ. ID. NO. 461, and an antisense region, wherein said antisense region consists of a sequence that is the complement of SEQ. ID. NO. 461;
- and (b) from zero to four overhang regions, wherein each overhang region is six or fewer nucleotides in length.
Dependencies are inferred from the claim text.